Correction

In the submission of the letter by Campbell and colleagues,¹ the authors provided statements of competing interests that were inadvertently omitted from the published letter. The competing interests statement should have read as follows:

Competing interests

Dr Gilbert has served on advisory boards, received research grant funding, and given lectures for AstraZeneca, Bristol-Myers Squibb, Merck, and Novartis. Dr Leiter has received research funding from, has provided continuing medical education on behalf of, or has acted as a consultant to AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Sanofi-Aventis, and Servier. Dr Larochelle has received support for continuing education and research grants from Amgen, AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Pfizer, and Takeda. Dr Tobe has received research grants and speaker’s honoraria from Abbott Laboratories, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Merck, Novartis, Pfizer, Sanofi-Aventis, and Servier. None of the other authors has any competing interests to declare.

Canadian Family Physician apologizes for any confusion this might have caused.

Reference

1. Campbell NRC, Gilbert RE, Leiter LA, Larochelle P, Tobe S, Chockalingam A, et al. Hypertension revisited [Letters]. Can Fam Physician 2012;58:635–6.